Cognition Therapeutics, Inc. CGTX
0.69 USD +0.05 (+8.12%)
At closeNov 6, 2026, 6:18 PM EST
0.67 -0.02 -2.46%
After hours · Nov 6, 6:18 PM ET
0.632 Day range 0.6975
0.595 52-week range 1.80
- YTD
- -49.11%
- 1 year
- -58.61%
- Market cap
- 65.33M
- EPS (ttm)
- -0.16
- Shares out
- 41.55M
- Forward P/E
- -0.80
- YTD return
- -49.11%
- 1-year return
- -58.61%
- Volume
- 282.75K
- Avg volume
- 503.05K
- Open
- 0.645
- Previous close
- 0.6354
- Day's range
- 0.632 – 0.6975
- 52-week range
- 0.595 – 1.80
- Beta
- 1.33
- Analysts
- Strong Buy
- Price target
- 6.50 (+846.1%)
- Earnings date
- Aug 8, 2024
1Y -0.9730 (-58.61%)
Key statistics
- Enterprise value
- -7.19M
- PEG ratio
- 0.00
- Price / sales
- 0.00
- Price / book
- 0.81
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Revenue growth
- 0.00%
- Free cash flow
- -29.72M
- Total cash
- 28.53M
- Total debt
- 809.00K
- Return on equity
- -108.31%
- Short % of float
- 2.94%
- 50-day average
- 0.47888
- 200-day average
- 1.23
Analyst view
Consensus: strong buy
Strong buy
Price target (mean) 6.50 +846.1% upside
Now 0.687
- Target (low)
- 1.50
- Target (mean)
- 6.50
- Target (high)
- 11.00
Ratings (0m) 5 5 buy · 0 hold · 0 sell
- Strong buy1
- Buy4
- Hold0
- Sell0
- Strong sell0
Next earnings
Aug 8, 2024
Expected Aug 8, 2024. Consensus EPS estimate -0.185.
Financials — quick view
CGTX Revenue — quarterly 0
CGTX Net income — quarterly -4.14M
CGTX EPS — quarterly -0.04
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 13, 2024 | Sep 1, 2024 | -0.24 | -0.25 | -0.01 | -4.17% |
| Aug 8, 2024 | Jun 1, 2024 | -0.22 | — | — | — |
| Aug 8, 2024 | Jun 1, 2024 | -0.22 | -0.18 | +0.04 | +18.18% |
| May 7, 2024 | Mar 1, 2024 | -0.23 | -0.27 | -0.04 | -17.39% |
| May 7, 2024 | Mar 1, 2024 | -0.23 | — | — | — |
| Mar 26, 2024 | Dec 1, 2023 | -0.38 | — | — | — |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 19, 2024 | B. Riley Securities | up | Neutral | Buy |
| Dec 19, 2024 | Chardan Capital | main | Buy | Buy |
| Dec 19, 2024 | HC Wainwright & Co. | main | Buy | Buy |
| Nov 27, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Nov 15, 2024 | Chardan Capital | main | Buy | Buy |
| Nov 4, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Cognition Therapeutics, Inc.
Cognition Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of small molecule therapeutics targeting age-related degenerative diseases and disorders of the central nervous system and retina. Its lead product candidate is CT1812, an orally delivered molecule modulator designed to penetrate the blood-brain barrier and bind selectively to the S2R complex, which is in Phase 2 clinical trial for the treatment of Alzheimer's disease, as well as geographic atrophy secondary to dry age-related macular degeneration and synucleinopathies, such as dementia with Lewy bodies. The company was incorporated in 2007 and is headquartered in Purchase, New York.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- cogrx.com
News
Cognition Therapeutics, Inc. (CGTX) Q3 2026 Earnings Call Transcript 
Cognition Therapeutics Q3 EPS $(0.04) Beats $(0.07) Estimate 
Cognition Therapeutics Reports Financial Results for the Third Quarter 2026 and Provides Business Update 
Cognition Therapeutics to Host Third Quarter 2026 Financial Results and Business Update Call on November 5, 2026 
Cognition Therapeutics Aligns With FDA On Key Elements Of Phase 3 Study In Dementia With Lewy Bodies Including Patient Selection, Dose, Duration, And Endpoints 
Cognition Therapeutics Receives U.S. Patent Covering A Polymorph Version Of Its Lead Drug Candidate Zervimesine 
Cognition Therapeutics' Type C Meeting With FDA To Take Place Oct. 20 For Planned Trial Of Zervimesine 
Cognition Therapeutics Q2 EPS $(0.04) Beats $(0.06) Estimate 
12 Health Care Stocks Moving In Wednesday's Intraday Session - FDA Agrees Psychosis Associated With Dementia With Lewy Bodies May Be Approvable Outcome, Reaches Alignment With Cognition Therapeutics On Vital Aspects To Support Its New Drug Application
Your note
Sign in to keep a note on CGTX — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CAGGIANO ANTHONY | Officer | Stock Award(Grant) | Feb 14, 2024 | 141,629 |
| DOYLE JOHN BRENDAN | Chief Financial Officer | Stock Award(Grant) | Feb 14, 2024 | 129,824 |
| FLETCHER AARON G.L. | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Jun 6, 2024 | 0 |
| KHATTAR JACK A | Director | Stock Award(Grant) | Jun 6, 2024 | 14,500 |
| KREIS LESLIE W JR | Director and Beneficial Owner of more than 10% of a Class of Security | Stock Award(Grant) | Nov 7, 2023 | 0 |
| MONIA BRETT P | Director | Stock Award(Grant) | Jun 6, 2024 | 14,500 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Group Inc | 2.99% | 1,242,554 | 762.93K | Sep 29, 2024 |
| Alyeska Investment Group, L.p. | 1.20% | 500,000 | 307.00K | Sep 29, 2024 |
| Geode Capital Management, LLC | 0.78% | 323,643 | 198.72K | Sep 29, 2024 |
| CM Management, LLC | 0.60% | 250,000 | 153.50K | Sep 29, 2024 |
| American Financial Group Inc. | 0.49% | 205,000 | 125.87K | Sep 29, 2024 |
| UBS Group AG | 0.48% | 197,859 | 121.48K | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 2.43% | 1,009,905 | 620.08K | Sep 29, 2024 |
| Vanguard Extended Market Index Fund | 0.48% | 200,577 | 123.15K | Sep 29, 2024 |
| Fidelity Extended Market Index Fund | 0.46% | 192,260 | 118.05K | Oct 30, 2024 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.18% | 76,700 | 47.09K | Sep 29, 2024 |
| iShares Micro Cap ETF | 0.17% | 71,610 | 43.97K | Oct 30, 2024 |
| Fidelity Total Market Index Fund | 0.14% | 59,268 | 36.39K | Oct 30, 2024 |